What is claimed is:

1. A compound represented by formula I,

$$X \longrightarrow \mathbb{R}^{5}$$

$$X \longrightarrow \mathbb{R}^{4}$$

$$X \longrightarrow \mathbb{R}^{2}$$

$$X \longrightarrow \mathbb{R}^{2}$$

$$X \longrightarrow \mathbb{R}^{2}$$

or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein,

each W is independently N or CR1;

each R¹ is independently selected from -H, halogen, trihaloalkyl, -CN, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁷, -NC(O)R⁶, -NCO₂R⁶, -C(O)R⁷, -R⁷, and -A-R⁷; provided at least one of R¹ is -A-R⁷, wherein, only for said at least one -A-R⁷, R⁷ must be an optionally substituted heteroalicyclic ring, and any nitrogen of said optionally substituted heteroalicyclic ring cannot be directly bound to A;

A is O, $S(O)_{0-2}$, and NR^6 ;

L is O, $S(O)_{0-2}$, or NR^3 ;

Q is C or N, when Q is N, then R⁴ does not exist;

 R^2 and R^3 are each independently -H or - R^7 ;

 R^4 and R^5 are each independently selected from -H, -OR⁶, -NR⁶R⁷, -S(O)₀₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -N(R⁶)SO₂R⁶, -NC(O)R⁶, -NCO₂R⁶, -C(O)R⁷, -CN, -NO₂, -NH₂, halogen, trihalomethyl, and -R⁷; or

R⁴ and R⁵, when taken together, form a five or six-membered aromatic ring system containing between zero and two nitrogens, said five or six-membered aromatic ring system optionally substituted with between zero and four of R¹⁵;

 R^6 is selected from -H, optionally substituted C_{1-8} alkyl, optionally substituted aryl C_{1-8} alkyl, optionally substituted heterocyclyl C_{1-8} alkyl, optionally substituted aryl, and optionally substituted heterocyclyl;

 R^7 is selected from -H, optionally substituted C_{1-8} alkyl, optionally substituted aryl C_{1-8} alkyl, optionally substituted heterocyclyl C_{1-8} alkyl, optionally substituted aryl, and optionally substituted heterocyclyl; provided that there are at least two carbons between any heteroatom of R^7 and A or either nitrogen to which R^2 or R^3 are attached; or

R⁶ and R⁷, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclic ring, said optionally substituted five- to seven-membered heterocyclic ring optionally containing at least one additional heteroatom selected from nitrogen, oxygen, sulfur, and phosphorus;

 R^8 is -H, -NO₂, -CN, -OR⁶, and optionally substituted C_{1-8} alkyl;

X is selected from one of the following six formulae:

wherein m is zero to five, n is zero to three, and Z is N or CR¹⁰;

 R^{10} is selected from -H, halogen, trihalomethyl, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -NC(O)R⁶, -NCO₂R⁶, -C(O)R⁷, and R⁷; K is O, S, or NR¹¹;

 R^{11} is selected from cyano, -NO₂, -OR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(O)R⁷, and R⁶; and

each R^{15} is independently selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -NC(O)R⁶, -NCO₂R⁶, -C(O)R⁷, and R⁷.

- 2. The compound according to claim 1, wherein L is NR³.
- 3. The compound according to claim 2, wherein K is either O or NR¹¹.

4. The compound according to claim 3, wherein R^2 and R^3 are each independently selected from -H and optionally substituted C_{1-8} alkyl, wherein substitution on the C_{1-8} alkyl of optionally substituted C_{1-8} alkyl is selected from -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -NC(O)R⁶, -NCO₂R⁶, -C(O)R⁷, heterocyclic, alicyclic, and aryl.

- 5. The compound according to claim 4, wherein R^2 and R^3 are -H.
- 6. The compound according to claim 5, wherein only one of R^1 is -A- R^7 , where A is selected from O, $S(O)_{0-1}$, and NR^6 ; and for -A- R^7 , R^7 is an optionally substituted heteroalicyclic ring.
- 7. The compound according to claim 6, wherein R^6 is selected from -H and $C_{1.8}$ alkyl, said $C_{1.8}$ alkyl optionally substituted with one or more groups each independently selected from -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -NC(O)R⁶, -NCO₂R⁶, -C(O)R⁷, heterocyclic, alicyclic, and aryl; and R⁷ of -A-R⁷ is selected from the following optionally substituted heteroalicyclics: azetidine, perhydroazepinyl, piperidinyl, piperazinyl, azabicyclo[3.2.1]octyl, octahydrocyclopenta[c]pyrrole, 2-oxopiperidinyl, 2-oxopyrrolidinyl, pyrrolidinyl, dihydropyridinyl, tetrahydropyridinyl, tetrahydropyranyl, thiamorpholinyl sulfone, and dioxaphospholanyl.
- 8. The compound according to claim 7, wherein X is

m is 0 to 3, and R^{10} is selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -NC(O)R⁶, -NCO₂R⁶, -C(O)R⁷, and optionally substituted C₁₋₈alkyl; said C₁₋₈alkyl optionally substituted with one or more groups each independently selected from -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -NC(O)R⁶, -NCO₂R⁶, -C(O)R⁷, heterocyclic, alicyclic, and aryl.

9. The compound according to claim 8, of formula II:

wherein:

A, R⁴, R⁵, R¹⁰, and m are as defined above;

 R^7 is selected from optionally substituted perhydroazepinyl, optionally substituted piperidinyl, optionally substituted pyrrolidinyl, and optionally substituted azetidine; wherein the ring nitrogen of R^7 is substituted with a group R^{12} ; and

 R^{12} is selected from -H, optionally substituted C_{1-8} alkyl, $-SO_2R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)R^7$, and an optionally substituted three- or four-carbon bridge between the ring nitrogen of R^7 and a carbon vicinal to the ring nitrogen of R^7 ; said three- or four-atom bridge optionally containing an oxygen in substitution for a carbon of the bridge.

10. The compound according to claim 9, wherein -A-R⁷ is selected from the following formulae:

wherein R^{12} is a C_{1-4} alkyl; R^{13} is selected from -H, an optionally substituted alkoxy group, an optionally substituted amino group, and an optionally substituted heteroalicyclic, with the proviso that a heteroatom of said optionally substituted alkoxy group, said optionally substituted amino group, or said optionally substituted heteroalicyclic cannot be attached to a carbon of R^{12} which is directly attached to the ring nitrogen of R^{7} ; and R^{14} is selected

from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -S(O)₀₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -NC(O)R⁶, -NCO₂R⁶, -C(O)R⁷, and optionally substituted C₁₋₆alkyl.

- 11. The compound according to claim 10, wherein A is -NR⁶- where R⁶ is selected from -H and C_{1-8} alkyl, said C_{1-8} alkyl substituted with at least one of -CO₂H and -CO₂C₁₋₈alkyl.
- 12. The compound according to claim 11, of formula III.

- 13. The compound according to claim 12, wherein R^{12} is a C_{2-4} alkyl; R^{13} is as defined above; R^{10} is is selected from -H, halogen, perfluoroalkyl, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -NC(O)R⁶, -NCO₂R⁶, -C(O)R⁷; R⁴ and R⁵ are each independently selected from -H, halogen, and C_{1-4} alkyl; or R⁴ and R⁵ combined are an optionally substituted phenyl; and m is 0-3.
- 14. The compound according to claim 13, wherein R^{12} is an ethylene; R^{10} is halogen; R^4 and R^5 are each independently selected from -H, halogen, and C_{1-2} alkyl; and m is 1-3.
- 15. The compound according to claim 14, wherein each R^{10} is independently selected from fluorine and chlorine; R^4 and R^5 are each independently selected from -H and $C_{1.2}$ alkyl; and m is 1-3.
- 16. The compound according to claim 15, wherein each R¹⁰ is independently selected from fluorine and chlorine; R⁴ and R⁵ are each independently selected from -H and -CH₃; and m is 1-2.
- 17. The compound according to claim 16, wherein R¹⁰ is fluorine; R⁴ and R⁵ are each independently selected from -H and -CH₃; and m is 1.

18. The compound according to claim 1, selected from the following:

| Entry | Name | Structure |
|-------|---|---|
| 1 | (3Z)-3-[[5-(methyloxy)-1H- benzimidazol-2- yl](phenyl)methylidene]-5-{[1- (phenylmethyl)pyrrolidin-3-yl]amino}- 1,3-dihydro-2H-indol-2-one | |
| 2 | (3Z)-5-[(1-ethylpiperidin-3-yl)amino]- 3-[[5-(methyloxy)-1H-benzimidazol-2- yl](phenyl)methylidene]-1,3-dihydro- 2H-indol-2-one | |
| 3 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[5-(methyloxy)-1H-benzimidazol-2- yl](phenyl)methylidene]-1,3-dihydro- 2H-indol-2-one | |
| 4 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[1H-imidazol-2- yl(phenyl)methylidene]-1,3-dihydro- 2H-indol-2-one | |
| 5 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-{[5-(methyloxy)-1H-benzimidazol- 2-yl][4- (methyloxy)phenyl]methylidene}-1,3- dihydro-2H-indol-2-one | N H N N N N N N N N N N N N N N N N N N |
| 6 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[5-(methyloxy)-1H-benzimidazol-2- yl](4-methylphenyl)methylidene]-1,3- dihydro-2H-indol-2-one | N H O H O O O O O O O O O O O O O O O O |

| | | |
|----|--|--|
| 7 | (3Z)-3-[1H-benzimidazol-2-yl(4- nitrophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | O ₂ N N N N N N N N N N N N N N N N N N N |
| 8 | (3Z)-3-{1H-benzimidazol-2-yl[4- (methyloxy)phenyl]methylidene}-5- [(1-ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | H H H |
| 9 | (3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | |
| 10 | (3Z)-3-[[5-(methyloxy)-1H- benzimidazol-2- yl](phenyl)methylidene]-5-[(2,2,6,6- tetramethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | HN N N N N N N N N N N N N N N N N N N |
| 11 | (3Z)-3-[(4-aminophenyl)(1H- benzimidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | H ₂ N H N H |
| 12 | (3Z)-3-[1H-benzimidazol-2-yl(4- methylphenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | NO HOLLOW |

| 13 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[1H-imidazol-2-yl(4- methylphenyl)methylidene]-1,3- dihydro-2H-indol-2-one | H C H C H C H C H C H C H C H C H C H C |
|----|--|---|
| 14 | (3Z)-5-[(1-ethylpiperidin-4-yl)oxy]-3- [[5-(methyloxy)-1H-benzimidazol-2- yl](phenyl)methylidene]-1,3-dihydro- 2H-indol-2-one | |
| 15 | (3Z)-5-[(1-ethylplperidin-4-yl)amino]- 3-{1H-imidazol-2-yl[4- (methyloxy)phenyl]methylidene}-1,3- dihydro-2H-indol-2-one | |
| 16 | (3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one | |
| 17 | (3Z)-3-[1H-benzimidazol-2-yl(3,5- difluorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | |
| 18 | (3Z)-3-[1H-benzimidazol-2-yl(3- fluorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | F N N N N N N N N N N N N N N N N N N N |

| 19 | (3Z)-3-[1H-benzimidazol-2-yl(3- nitrophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | |
|----|---|--|
| 20 | 3-((Z)-1H-benzimidazol-2-yl{5-[(1- ethylpiperidin-4-yl)amino]-2-oxo-1,2- dihydro-3H-indol-3- ylidene}methyl)benzonitrile | NC N N N N N N N N N N N N N N N N N N |
| 21 | (3Z)-3-[(3-aminophenyl)(1H- benzimidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | H ₂ N N N N N N N N N N N N N N N N N N N |
| 22 | (3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-(piperidin- 4-ylamino)-1,3-dihydro-2H-indol-2- one | HN HN PO |
| 23 | 3-((Z)-1H-benzimidazol-2-yl{5-[(1- ethylpiperidin-4-yl)amino]-2-oxo-1,2- dihydro-3H-indol-3- ylidene}methyl)benzenecarboximida mide | H ₂ N NH |
| 24 | (3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |

| 25 | (3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-[(2,2,6,6- tetramethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | |
|----|--|--|
| 26 | (3Z)-3-{1H-benzimidazol-2-yl[3- (methyloxy)phenyl]methylidene}-5- [(1-ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | |
| 27 | (3Z)-3-[1H-benzimidazol-2-yl(3- chlorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | CI N N N N N N N N N N N N N N N N N N N |
| 28 | 2-(2-{2-[(Z)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene}(phenyl)methyl]-1H-imidazol-4-yl}ethyl)-1H-isoindole-1,3(2H)-dione | N H N O Y O |
| 29 | (3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-({1-[2- (dimethylamino)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |
| 30 | (3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-{[1- (methylsulfonyl)piperidin-4-yl]amino}- 1,3-dihydro-2H-indol-2-one | |

| 31 | (3Z)-5-(8-azabicyclo[3.2.1]oct-3- ylamino)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-1,3-dihydro- 2H-indol-2-one | HZ ZH |
|----|---|---|
| 32 | (3Z)-3-{1H-benzimidazol-2-yl[3- (methyloxy)phenyl]methylidene}-5- [(1-ethylpiperidin-4-yl)oxy]-1,3- dihydro-2H-indol-2-one | |
| 33 | (3Z)-3-[1H-benzimidazol-2-yl(3,5- difluorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)oxy]-1,3-dihydro- 2H-indol-2-one | F N N N N N N N N N N N N N N N N N N N |
| 34 | (3Z)-3-[1H-benzimidazol-2- yl(phenyl)methylidene]-5-{[1- (phenylmethyl)piperidin-4-yl]oxy}-1,3- dihydro-2H-indol-2-one | |
| 35 | (3Z)-3-[1H-benzimidazol-2-yl(3- chlorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)oxy]-1,3-dihydro- 2H-indol-2-one | CI NHO |
| 36 | (3Z)-3-[1H-benzimidazol-2-yl(3,5- difluorophenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4-yl}oxy)- 1,3-dihydro-2H-indol-2-one | |

| 37 | (3Z)-3-[1H-benzimidazol-2-yl(3- chlorophenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4-yl}oxy)- 1,3-dihydro-2H-indol-2-one | CI |
|----|--|---|
| 38 | (3Z)-3-[1H-benzimidazol-2-yl(3- chlorophenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |
| 39 | (3Z)-3-{1H-benzimidazol-2-yl[3- (methyloxy)phenyl]methylidene}-5- ({1-[2-(methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |
| 40 | (3Z)-3-[(3-chlorophenyl)(1H-imidazol- 2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |
| 41 | (3Z)-3-[(3-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | P N N N N N N N N N N N N N N N N N N N |
| 42 | (3Z)-3-[1H-benzimidazol-2-yl(3,5- difluorophenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |

| 43 | (3Z)-3-[1H-benzimidazol-2-yl(3- chlorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)(methyl)amino]- 1,3-dihydro-2H-indol-2-one | |
|----|---|--|
| 44 | (3Z)-3-[(3-chlorophenyl)(1H-imidazol- 2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)oxy]-1,3-dihydro- 2H-indol-2-one | CICAL |
| 45 | (3Z)-3-[1H-benzimidazol-2-yl(4- chlorophenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | CI NHO |
| 46 | (3Z)-3-[1H-benzimidazol-2-yl(3- fluorophenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |
| 47 | (3Z)-3-[1H-benzimidazol-2-yl(4- fluorophenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |
| 48 | (3Z)-3-[(3-chlorophenyl)(1H-imidazol- 2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | CI N N N N N N N N N N N N N N N N N N N |

| 49 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(3-fluorophenyl)(1H-imidazol-2- yl)methylidene]-1,3-dihydro-2H-indol- 2-one | F N N N N N N N N N N N N N N N N N N N |
|----|---|---|
| 50 | (3Z)-3-[1H-benzimidazol-2-yl(3- fluoro-4-methylphenyl)methylidene]- 5-[(1-ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | |
| 51 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(3-fluorophenyl)(4-methyl-1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one | F N N N N N N N N N N N N N N N N N N N |
| 52 | (3Z)-3-[1H-benzimidazol-2-yl(4- fluoro-3-methylphenyl)methylidene]- 5-[(1-ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | L N N N N N N N N N N N N N N N N N N N |
| 53 | (3Z)-3-[(3-chloro-4-fluorophenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | E Z ZH O |
| 54 | (3Z)-3-[(3,4-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | F N N N N N N N N N N N N N N N N N N N |

| 55 | (3Z)-3-[(5-chloro-1H-benzimidazol-2- yl)(phenyl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | N H CI |
|----|---|--|
| 56 | (3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one | F N CI |
| 57 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(3-fluoro-4-methylphenyl)(1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one | H N N N N N N N N N N N N N N N N N N N |
| 58 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(4-fluorophenyl)(1H-imidazol-2- yl)methylidene]-1,3-dihydro-2H-indol- 2-one | THE NAME OF THE PARTY OF THE PA |
| 59 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[1H-imidazol-2-yl(4- propylphenyl)methylidene]-1,3- dihydro-2H-indol-2-one | |
| 60 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-{1H-imidazol-2-yl[4- (trifluoromethyl)phenyl]methylidene}- 1,3-dihydro-2H-indol-2-one | F ₃ C N N N N N N N N N N |

| 61 | (3E)-3-[(3,5-difluorophenyl)(5-fluoro- 1H-benzimidazol-2-yl)methylidene]- 5-[(1-ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | F P P P P P P P P P P P P P P P P P P P |
|----|--|---|
| 62 | (3Z)-3-[(3,5-difluorophenyl)(5-fluoro- 1H-benzimidazol-2-yl)methylidene]- 5-[(1-ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | F N F N H |
| 63 | (3Z)-3-[(3-fluoro-4-methylphenyl)(1H- imidazol-2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |
| 64 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(4-methyl-1H-imidazol-2-yl)(4- methylphenyl)methylidene]-1,3- dihydro-2H-indol-2-one | |
| 65 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[3-fluoro-4- (trifluoromethyl)phenyl](1H-imidazol- 2-yl)methylidene]-1,3-dihydro-2H- indol-2-one | F ₃ C N N N |

| | | |
|----|--|--|
| 66 | (3Z)-3-[(4-chlorophenyl)(1H-imidazol- 2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | CI N H |
| 67 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(3-fluoro-4-methylphenyl)(4- methyl-1H-imidazol-2- yl)methylidene]-1,3-dihydro-2H-indol- 2-one | F N N N N N N N N N N N N N N N N N N N |
| 68 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-{1H-imidazol-2-yl[6- (trifluoromethyl)pyridin-3- yl]methylidene}-1,3-dihydro-2H-indol- 2-one | F ₃ C N N N N N N |
| 69 | (3Z)-3-[1H-imidazol-2-yl(4- methylphenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |
| 70 | (3Z)-3-[(3-fluorophenyl)(4-methyl-1H- imidazol-2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |
| 71 | (3Z)-3-{1H-imidazol-2-yl[4- (trifluoromethyl)phenyl]methylidene}- 5-({1-[2-(methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | F ₃ C N N N N N N N N N N N N |

| 72 | (3Z)-3-[(5-chloro-1H-benzimidazol-2- yl)(phenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |
|----|--|---|
| 73 | (3Z)-3-[(3,5-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | F N N N N N N N N N N N N N N N N N N N |
| 74 | (3Z)-3-[(3,5-difluorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | F N N N N N N N N N N N N N N N N N N N |
| 75 | (3Z)-3-[(3,5-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |
| 76 | (3Z)-3-[(3,5-difluorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-({1- [2-(methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |

| 77 | (3Z)-3-[(4-methyl-1H-imidazol-2- yl)(4-methylphenyl)methylidene]-5- ({1-[2-(methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |
|----|--|--|
| 78 | (3Z)-3-[(4-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | F N N N N N N N N N N N N N N N N N N N |
| 79 | (3Z)-3-[(3,4-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |
| 80 | (3Z)-3-[(3-chloro-4-fluorophenyl)(1H- imidazol-2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | CI N N N N N N N N N N N N N N N N N N N |
| 81 | (3Z)-3-[(3-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-(piperidin-4- ylamino)-1,3-dihydro-2H-indol-2-one | HN N H |
| 82 | (3Z)-3-[(3-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-{[1-(2-piperidin- 1-ylethyl)piperidin-4-yl]amino}-1,3- dihydro-2H-indol-2-one | N N N N N N N N N N N N N N N N N N N |

| 83 | (3Z)-3-[(3-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-{[1-(2-morpholin- 4-ylethyl)piperidin-4-yl]amino}-1,3- dihydro-2H-indol-2-one | P N N H O N H |
|----|--|---|
| 84 | (3Z)-5-({1-[2- (diethylamino)ethyl]piperidin-4- yl}amino)-3-[(3-fluorophenyl)(1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one | F N N N N N N N N N N N N N N N N N N N |
| 85 | (3Z)-3-[(3-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-{[1-(2-pyrrolidin- 1-ylethyl)piperidin-4-yl]amino}-1,3- dihydro-2H-indol-2-one | F N N N N N N N N N N N N N N N N N N N |
| 86 | (3Z)-3-{1H-imidazol-2-yl(4- methylphenyl)methylidene]-5-[(1- methylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | |
| 87 | (3Z)-3-[(3-fluorophenyl)(1H-1,2,4- triazol-5-yl)methylidene]-5-((1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | N N N N N N N N N N N N N N N N N N N |
| 88 | ethyl 2-{(Z)-(3-fluorophenyl)[5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-2-oxo-1,2-dihydro-3H- indol-3-ylidene]methyl}-4-methyl-1H- imidazole-5-carboxylate | |

| 89 | (3Z)-3-[1H-imidazol-2- yl(phenyl)methylidene]-5-({1-{2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |
|----|---|--|
| 90 | (3Z)-3-{1H-imidazol-2-yl[4- (methyloxy)phenyl]methylidene}-5- ({1-[2-(methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |
| 91 | (3Z)-3-[(4-chlorophenyl)(1H-imidazol- 2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | CI NHON |
| 92 | (3Z)-3-[[3-fluoro-4- (trifluoromethyl)phenyl](1H-imidazol- 2-yl)methylidene]-5-([1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | F ₃ C N N N N N N |
| 93 | (3Z)-3-[(3-fluorophenyl)(1H-imidazol- 2-yl)methylidene]-5-{[1- (methylsulfonyl)piperidin-4-yl]amino}- 1,3-dihydro-2H-indol-2-one | F N N N N N N N N N N N N N N N N N N N |
| 94 | (3Z)-3-[1H-imidazol-2-yl(4- propylphenyl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |

| 95 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(3-fluorophenyl)(4-phenyl-1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one | |
|-----|---|---|
| 96 | (3Z)-3-[(3-fluorophenyl)(4-phenyl-1H- imidazol-2-yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | F H N N N N N N N N N N N N N N N N N N |
| 97 | (3Z)-3-[(3-fluoro-4-methylphenyl)(4- methyl-1H-imidazol-2- yl)methylidene]-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | |
| 98 | (3Z)-3-{1H-imidazol-2-yl[6- (trifluoromethyl)pyridin-3- yl]methylidene}-5-({1-[2- (methyloxy)ethyl]piperidin-4- yl}amino)-1,3-dihydro-2H-indol-2-one | F ₃ C N N N N |
| 99 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(3-fluorophenyl)(1H-1,2,4-triazol- 5-yl)methylidene]-1,3-dihydro-2H- indol-2-one | F N N N N N N N N N N N N N N N N N N N |
| 100 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[2-fluoro-4- (trifluoromethyl)phenyl](1H-imidazol- 2-yl)methylidene]-1,3-dihydro-2H- indol-2-one | F ₃ C F N N H |

| 101 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-{(4-methyl-1H-imidazol-2-yl)[4- (trifluoromethyl)phenyl]methylidene}- 1,3-dihydro-2H-indol-2-one | F ₃ C ZTHO |
|-----|---|--|
| 102 | (3Z)-3-[(4-chlorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | CC ZZH OZH |
| 103 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[3-fluoro-4- (trifluoromethyl)phenyl](4-methyl-1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one | F ₃ C F HN ZH O |
| 104 | (3Z)-3-[(3,4-difluorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | F N N N N N N N N N N N N N N N N N N N |
| 105 | (3Z)-3-[(3-chloro-4-fluorophenyl)(4- methyl-1H-imidazol-2- yl)methylidene]-5-[(1-ethylpiperidin- 4-yl)amino]-1,3-dihydro-2H-indol-2- one | CI NH NH |
| 106 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(4-fluorophenyl)(4-methyl-1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one | THE STATE OF THE S |

| | · | |
|-----|---|--|
| 107 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[(2-fluorophenyl)(1H-imidazol-2- yl)methylidene]-1,3-dihydro-2H-indol- 2-one | H N N N N N N N N N N N N N N N N N N N |
| 108 | (3Z)-5-[(1-ethylpiperidin-4-yl)amino]- 3-[[2-fluoro-4- (trifluoromethyl)phenyl](4-methyl-1H- imidazol-2-yl)methylidene]-1,3- dihydro-2H-indol-2-one | F ₃ C H N N N N N |
| 109 | (3Z)-3-[(2,3-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | HZ ZH O |
| 110 | (3Z)-3-[(2,3-difluorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | TZ ZH O ZH |
| 111 | (3Z)-3-[(2,4-difluorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | L Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z |
| 112 | (3Z)-3-[(2,4-difluorophenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | H N N N N N N N N N N N N N N N N N N N |

| | | F |
|-----|---|--|
| 113 | (3Z)-3-[(2-fluorophenyl)(4-methyl- 1H-imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | |
| 114 | (3Z)-3-[(3-trifluoromethylphenyl)(1H- imidazol-2-yl)methylidene]-5-[(1- ethylpiperidin-4-yl)amino]-1,3- dihydro-2H-indol-2-one | F ₃ C N N N N N N N N N N N N N N N N N N N |
| 115 | (3Z)-3-[(3-trifluoromethylphenyl)(4- methyl-1H-imidazol-2- yl)methylidene]-5-[(1-ethylpiperidin- 4-yl)amino]-1,3-dihydro-2H-indol-2- one | F ₃ C N N N N N N N N N N N N N N N N N N N |
| 116 | (3Z)-3-[(2,4-dichloro-5-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one | C Z ZH O |
| 117 | (3Z)-3-[(2,4-dichloro-5-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one | CC ZZH OZH |
| 118 | (3Z)-3-[(4-chloro-2-fluorophenyl)(4- methyl-1H-imidazol-2- yl)methylidene]-5-[(1-ethylpiperidin- 4-yl)amino]-1,3-dihydro-2H-indol-2- one | CI P N N N N N N N N N N N N N N N N N N |

19. A pharmaceutical composition comprising a compound according to any one of claims 1-18 and a pharmaceutically acceptable carrier.

- 20. A metabolite of the compound or the pharmaceutical composition according to any one of claims 1-19.
- 21. A method of modulating the *in vivo* activity of a kinase, the method comprising administering to a subject an effective amount of the compound or the pharmaceutical composition according to any of claims 1-19.
- 22. The method according to claim 21, wherein the kinase is at least one of VEGF receptor 2 (Flk-1/KDR), FGFR1, and PDGFR (alpha and beta).
- 23. The method according to claim 22, wherein modulating the *in vivo* activity of the kinase comprises inhibition of said kinase.
- 24. A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described in any one of claims 1-19.
- 25. A method of screening for modulator of a kinase, the method comprising combining a compound according to any one of paragraphs 1-18, and at least one candidate agent and determining the effect of the candidate agent on the activity of said kinase.
- 26. A method of inhibiting proliferative activity in a cell, the method comprising administering an effective amount of a composition comprising a compound according to any one of claims 1-18 to a cell or a plurality of cells.